In a nutshell This study evaluated the side effects in patients with type 2 diabetes (T2D) after treatment with glimepiride (Amaryl). The authors found that while glimepiride lowered mortality, the rate of most side effects was the same as other similar drugs. Some background Treatments for T2D aim to lower blood glucose...
Read MoreIn a nutshell This trial is examining the effectiveness of tirzepatide compared to insulin glargine in patients with type 2 diabetes who are also at high risk for heart disease. The main outcome to be measured will be a change in HbA1c (a blood test that measures average blood sugar levels in the past 3 months) over 52 weeks. The details In type 2...
Read More
In a nutshell This review examined the risk of mortality associated with sulfonylureas in patients with type 2 diabetes. The authors concluded that sulfonylureas do not increase the risk of mortality or cardiovascular mortality. Some background Patients with type 2 diabetes (T2D) may be treated with medication to reduce blood glucose (sugar)...
Read More
In a nutshell The authors evaluated the risk of autoimmune disease development in patients starting a dipeptidyl peptidase inhibitor for type 2 diabetes. Some background Dipeptidyl peptidase-4 (DPP4) is a protein that plays a major role in glucose metabolism. DPP4-inhbitors such as linagliptin (Tradjenta), saxagliptin (Onglyza) and sitagliptin...
Read More
In a nutshell This study compared the effects of adding insulin glargine treatment to metformin (Glucophage), glimepiride (Amaryl) or their combination in patients with uncontrolled type 2 diabetes mellitus. Some background Hyperglycemia (high blood glucose) in type 2 diabetes mellitus arises from a combination...
Read More
